EP Patent

EP0811381A1 — A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof

Assigned to Antares Pharma NV · Expires 1997-12-10 · 28y expired

What this patent protects

Pharmaceutical formulation in the form of a gel suitable for the transdermal administration of an active agent of the class of estrogens or of progestin class or of a mixture of both, comprising: as permeation enhancers of the above said active agents a combination consistin…

USPTO Abstract

Pharmaceutical formulation in the form of a gel suitable for the transdermal administration of an active agent of the class of estrogens or of progestin class or of a mixture of both, comprising: as permeation enhancers of the above said active agents a combination consisting substantially of an aliphatic alcohol having general formula CH3(CH2)nCH2OH wherein n = 8-16 and of a monoalkylether of diethylene glycol; as a vehicle or carrier, a combination of an alkanol of 2÷4 C atoms, a glycol and water; as gelling agent a polymer or copolymer of acrylic acid; a tertiary amine as a thickening and neutralizing agent.

Drugs covered by this patent

Patent Metadata

Patent number
EP0811381A1
Jurisdiction
EP
Classification
—
Expires
1997-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Antares Pharma NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.